TABLE 1.
Model parameters: baseline values, ranges, and distributions for the sensitivity analysis.
| Parameter | Baseline value | Range | References | Distribution | |
|---|---|---|---|---|---|
| Minimum | Maximum | ||||
| Weibull survival model for OS of chemotherapy | |||||
| Overall population | Scale = 0.011708, shape = 1.432,984 | — | - | Modi et al. (2022) | - |
| Population with hormone receptor-positive | Scale = 0.011763, shape = 1.393,105 | - | - | Modi et al. (2022) | - |
| Population with hormone receptor-negative | Scale = 0.050763, shape = 1.129,492 | - | - | Modi et al. (2022) | - |
| Weibull survival model for PFS of chemotherapy | |||||
| Overall population | Scale = 0.164,483, shape = 0.903,477 | - | - | Modi et al. (2022) | - |
| Population with hormone receptor-positive | Scale = 0.141,586, shape = 0.945,576 | - | - | Modi et al. (2022) | - |
| Population with hormone receptor-negative | Scale = 0.25686, shape = 0.8906 | - | - | Modi et al. (2022) | - |
| Weibull survival model for OS of trastuzumab deruxtecan | |||||
| Overall population | Scale = 0.007249, shape = 1.431,054 | - | - | Modi et al. (2022) | - |
| Population with hormone receptor-positive | Scale = 0.004488, shape = 1.577,038 | - | - | Modi et al. (2022) | - |
| Population with hormone receptor-negative | Scale = 0.026802, shape = 1.097747 | - | - | Modi et al. (2022) | - |
| Weibull survival model for PFS of trastuzumab deruxtecan | |||||
| Overall population | Scale = 0.057066, shape = 1.074695 | - | - | Modi et al. (2022) | - |
| Population with hormone receptor-positive | Scale = 0.049346, shape = 1.116,918 | - | - | Modi et al. (2022) | - |
| Population with hormone receptor-negative | Scale = 0.11992, shape = 0.84977 | - | - | Modi et al. (2022) | - |
| Rate of post-discontinuation therapy | |||||
| Chemotherapy group | 0.081 | 0.065 | 0.097 | Modi et al. (2022) | Beta |
| Trastuzumab deruxtecan group | 0.162 | 0.130 | 0.194 | Modi et al. (2022) | Beta |
| Risk for main AEs in the chemotherapy group | |||||
| Risk of neutropenia | 0.407 | 0.326 | 0.488 | Modi et al. (2022) | Beta |
| Risk of leukopenia | 0.192 | 0.154 | 0.230 | Modi et al. (2022) | Beta |
| Risk of increased aminotransferase levels | 0.081 | 0.065 | 0.097 | Modi et al. (2022) | Beta |
| Risk for main AEs in the trastuzumab deruxtecan group | |||||
| Risk of neutropenia | 0.137 | 0.110 | 0.164 | Modi et al. (2022) | Beta |
| Risk of anemia | 0.081 | 0.065 | 0.097 | Modi et al. (2022) | Beta |
| Risk of fatigue | 0.075 | 0.060 | 0.090 | Modi et al. (2022) | Beta |
| Risk of leukopenia | 0.065 | 0.052 | 0.078 | Modi et al. (2022) | Beta |
| Risk of thrombocytopenia | 0.051 | 0.041 | 0.061 | Modi et al. (2022) | Beta |
| Utility | |||||
| Utility PFS | 0.700 | 0.560 | 0.840 | Lloyd et al. (2006); Le et al. (2016) | Beta |
| Utility PD | 0.500 | 0.400 | 0.600 | Lloyd et al. (2006); Le et al. (2016) | Beta |
| Disutility | |||||
| Neutropenia | 0.090 | 0.072 | 0.108 | Ding et al. (2021) | Beta |
| Leukopenia | 0.090 | 0.072 | 0.108 | Ding et al. (2021) | Beta |
| Anemia | 0.120 | 0.096 | 0.144 | Le et al. (2016) | Beta |
| Thrombocytopenia | 0.122 | 0.098 | 0.146 | Le et al. (2016) | Beta |
| Fatigue | 0.290 | 0.232 | 0.348 | Liu et al. (2021) | Beta |
| Increased aminotransferase levels | 0.308 | 0.246 | 0.370 | Wang et al. (2021) | Beta |
| Drug cost, $/per cycle | |||||
| Chemotherapy | 7,607 | 6,086 | 9,128 | CMS (2022) | Gamma |
| Trastuzumab deruxtecan | 20,114 | 16,091 | 24,137 | CMS (2022) | Gamma |
| Cost of AEs, $ | |||||
| Chemotherapy | 7,870 | 6,296 | 9,444 | Le et al. (2016); Wang et al. (2021); Zhu et al. (2021) | Gamma |
| Trastuzumab deruxtecan | 2,585 | 2,068 | 3,102 | Le et al. (2016); Wang et al. (2021); Zhu et al. (2021) | Gamma |
| Administration per cycle | 352 | 282 | 422 | Le et al. (2016) | Gamma |
| Follow-up per cycle | 1,980 | 1,584 | 2,376 | Zhang et al. (2019) | Gamma |
| Best supportive care per cycle | 3,358 | 2,686 | 4,029 | Wu et al. (2020) | Gamma |
| Immunohistochemical test per patient | 123 | 98 | 148 | Han et al. (2020) | Gamma |
| Terminal care per patient | 2,844 | 2,275 | 3,413 | Wang et al. (2021) | Gamma |
| Weight (kg) | 74 | 59 | 89 | Le et al. (2016) | Normal |
| Body surface area (meters2) | 1.82 | 1.46 | 2.18 | Le et al. (2016) | Normal |
| Discount rate | 0.03 | 0 | 0.05 | Ding et al. (2021) | Uniform |
Abbreviation: OS, overall survival; PFS, progression-free survival; PD, disease progressed; AEs, adverse events.